Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs

The development of clinically effective drugs that could complement existing vaccines is urgently needed to reduce the morbidity and mortality associated with COVID-19. Drug-metabolizing enzymes, membrane-associated drug transporters, and inflammatory responses can partly determine the safety and ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Nwabufo, Chukwunonso K., Bendayan, Reina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510059/
https://www.ncbi.nlm.nih.gov/pubmed/36374805
http://dx.doi.org/10.1016/j.tips.2022.09.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510059/
https://www.ncbi.nlm.nih.gov/pubmed/36374805
http://dx.doi.org/10.1016/j.tips.2022.09.005

Ejemplares similares